These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 22418886)

  • 1. Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil.
    Torres DM; Harrison SA
    Semin Liver Dis; 2012 Feb; 32(1):30-8. PubMed ID: 22418886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NAFLD leads to liver cancer: do we have sufficient evidence?
    Duan XY; Zhang L; Fan JG; Qiao L
    Cancer Lett; 2014 Apr; 345(2):230-4. PubMed ID: 23941829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron overload in nonalcoholic steatohepatitis.
    Fujita N; Takei Y
    Adv Clin Chem; 2011; 55():105-32. PubMed ID: 22126026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
    Massoud O; Charlton M
    Clin Liver Dis; 2018 Feb; 22(1):201-211. PubMed ID: 29128057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma.
    Kutlu O; Kaleli HN; Ozer E
    Can J Gastroenterol Hepatol; 2018; 2018():8543763. PubMed ID: 30228976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H; Tilg H
    Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection.
    Starley BQ; Calcagno CJ; Harrison SA
    Hepatology; 2010 May; 51(5):1820-32. PubMed ID: 20432259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obesity, insulin resistance, NASH and hepatocellular carcinoma.
    Yu J; Shen J; Sun TT; Zhang X; Wong N
    Semin Cancer Biol; 2013 Dec; 23(6 Pt B):483-91. PubMed ID: 23876851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
    Charrez B; Qiao L; Hebbard L
    World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
    Perumpail RB; Wong RJ; Ahmed A; Harrison SA
    Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocellular carcinoma development in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Is it going to be the "Plague" of the 21st century? A literature review focusing on pathogenesis, prevention and treatment.
    Argyrou C; Moris D; Vernadakis S
    J BUON; 2017; 22(1):6-20. PubMed ID: 28365930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HCC and NASH: how strong is the clinical demonstration?
    Rosmorduc O; Fartoux L
    Clin Res Hepatol Gastroenterol; 2012 Jun; 36(3):202-8. PubMed ID: 22326764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-viral causes of liver cancer: does obesity led inflammation play a role?
    Alzahrani B; Iseli TJ; Hebbard LW
    Cancer Lett; 2014 Apr; 345(2):223-9. PubMed ID: 24007864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis.
    Marengo A; Rosso C; Bugianesi E
    Annu Rev Med; 2016; 67():103-17. PubMed ID: 26473416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Fatty liver and global cardiometabolic risk].
    Szollár L
    Orv Hetil; 2010 Nov; 151(47):1946-50. PubMed ID: 21071306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development.
    Jiang CM; Pu CW; Hou YH; Chen Z; Alanazy M; Hebbard L
    World J Gastroenterol; 2014 Nov; 20(44):16464-73. PubMed ID: 25469014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obesity and liver cancer.
    Vanni E; Bugianesi E
    Clin Liver Dis; 2014 Feb; 18(1):191-203. PubMed ID: 24274874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obesity and hepatocellular carcinoma.
    Caldwell SH; Crespo DM; Kang HS; Al-Osaimi AM
    Gastroenterology; 2004 Nov; 127(5 Suppl 1):S97-103. PubMed ID: 15508109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.